Compare MBBC & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBBC | FEMY |
|---|---|---|
| Founded | 1902 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 37.2M |
| IPO Year | N/A | 2021 |
| Metric | MBBC | FEMY |
|---|---|---|
| Price | $14.00 | $0.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 1.8K | ★ 381.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.60 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,629,108.00 |
| Revenue This Year | N/A | $64.02 |
| Revenue Next Year | N/A | $147.19 |
| P/E Ratio | $47.11 | ★ N/A |
| Revenue Growth | N/A | ★ 51.97 |
| 52 Week Low | $9.94 | $0.31 |
| 52 Week High | $14.64 | $1.76 |
| Indicator | MBBC | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 61.97 | 42.05 |
| Support Level | $10.05 | $0.47 |
| Resistance Level | N/A | $0.58 |
| Average True Range (ATR) | 0.25 | 0.04 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 66.14 | 30.35 |
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.